Back Hepatitis B

Hepatitis B

PAS 2017: Children on Immunosuppressive Therapy May Lose Hepatitis B Vaccine Protection

More than half of children treated with immunosuppressive drugs for gastrointestinal or rheumatological conditions no longer had protective levels of antibodies against hepatitis B virus (HBV) and may require repeat vaccinations, according to a study presented at the Pediatric Academic Societies Meeting last week in San Francisco.

alt

Read more:

EASL 2017: Albumin Reduces Complications of Decompensated Cirrhosis and Improves Survival

Long-term administration of human album was associated with fewer serious complications, less hospitalization, better quality of life, and longer survival for people with decompensated liver cirrhosis, according to a report at the EASL International Liver Congress last month in Amsterdam.

alt

Read more:

EASL 2017: Switching to TAF for Hepatitis B Improves Kidney Function and Bone Loss

People with hepatitis B who switched from the old tenofovir disoproxil fumarate (TDF) to the new tenofovir alafenamide (TAF) saw improvements in kidney function biomarkers and recovery of bone loss, researchers reported at the EASL International Liver Congress last week in Amsterdam.

alt

Read more:

EASL 2017: Besifovir and Tenofovir Exalidex Look Promising for Hepatitis B

A pair of investigational nucleotide analog antivirals were shown to be active against hepatitis B virus (HBV) with minimal potential for kidney and bone toxicity, researchers reported at the EASL International Liver Congress last month in Amsterdam. Besifovir is in Phase 3 clinical trials, while tenofovir exalidex is in early development.

alt

Read more:

EASL 2017: Nivolumab Increases Survival for People with Advanced Liver Cancer

The checkpoint inhibitor nivolumab (Opdivo) produced durable responses, prolonged overall survival, and was generally well-tolerated as a treatment for advanced liver cancer that did not respond to standard therapy, researchers reported at the at the EASL International Liver Congress this week in Amsterdam.

alt

Read more:

EASL 2017: WHO Releases Global Hepatitis Report

An estimated 325 million people worldwide are living with chronic hepatitis B or hepatitis C, according to a new report from the World Health Organization (WHO) released at the EASL International Liver Congress last month in Amsterdam.Most lack access to testing and treatment, and therefore are at risk for liver disease progression, liver cancer, and death.

alt

Read more:

EASL 2017: International Liver Congress Starts This Week in Amsterdam

The European Association for the Study of the Liver (EASL) International Liver Congress (ILC 2016) will take place April 19-23 at the RAI Centre in Amsterdam. The congress is one of the major annual scientific meetings covering hepatitis B and C and its complications, as well as other liver diseases. HIVandHepatitis.com and our partners at aidsmap.com will be providing on-site coverage of meeting highlights.

alt

Read more:

EASL 2017: EASL Releases Updated Hepatitis B Guidelines at International Liver Congress

The European Association for the Study of the Liver (EASL) presented revised clinical practice guidelines for the management of hepatitis B virus (HBV) infection -- the first update since 2012 -- during a special session at its International Liver Congress last week in Amsterdam. For the first time the guidelines include tenofovir alafenamide (TAF) and present evidence about when and how to stop antiviral therapy.

alt

Read more:

AASLD 2016: Is Improved Treatment Reducing Liver Cancer Among People with Hepatitis B?

The incidence of hepatocellular carcinoma (HCC) appears to be decreasing and mortality improving among chronic hepatitis B patients treated with suppressive antiviral therapy, according to studies presented at the recent 2016 AASLD Liver Meeting in Boston. However, liver cancer remains a major indication for liver transplants and has a negative effect on survival of people with hepatitis B.

alt

Read more: